Skip to main content
. Author manuscript; available in PMC: 2014 Jun 27.
Published in final edited form as: Eur J Endocrinol. 2010 Nov 8;164(2):157–167. doi: 10.1530/EJE-10-0754

Table 1.

Mass spectrometry of protein spots that changed significantly after treatment.

Spot Gel
(pI/MW)		 Identity match Accession
no.		 % Of
changea 		MS
scoreb 		Max
sequence
coverage
(%)		 Matched
fragments		 MS/MS
scorec 		Max
sequence
coverage
(%)		 Matched
fragments
A 6.0/15 Transthyretin P02766 K20.60 172 95 13/40 767 87 9/52
B 6.4/15 Transthyretin P02766 K27.04 150 87 10/26 314 67 6/35
C 6.2/20 Haptoglobin a2 P00738 K39.92 103 39 10/47 394 22 6/59
D 7.8/12 b-Hemoglobin Q14484 K22.67 66 58 8/31 64 6 6/31
E 5.0/10 ApoA-1 P02647 K33.65 158 48 14/38 170 24 5/52
F 5.4/10 ApoA-1 P02647 K28.24 160 51 15/39 292 26 6/53
G 7.5/35 Complement C4B precursord P0C0L 52.38 77 1 2/27
a

Percentage (%) of change was calculated dividing the post-treatment mean intensities over the pre-treatment mean values.

b

A minimum MS score O64 was considered significant.

c

A minimum of two significant MS/MS peptide fragments was considered to assign an ID for a spot.

d

Spot G was identified as complement C4B precursor based on the protein score obtained by ProteinPilot.